solifenacin succinate has been researched along with quinuclidines in 238 studies
| Studies (solifenacin succinate) | Trials (solifenacin succinate) | Recent Studies (post-2010) (solifenacin succinate) | Studies (quinuclidines) | Trials (quinuclidines) | Recent Studies (post-2010) (quinuclidines) |
|---|---|---|---|---|---|
| 522 | 194 | 343 | 2,567 | 453 | 991 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 122 (51.26) | 29.6817 |
| 2010's | 116 (48.74) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ikeda, K; Kobayashi, S; Miyata, K; Suzuki, M; Yamada, T | 1 |
| Fujii, T; Kawashima, K | 1 |
| Honda, K; Ikeda, K; Kobayashi, S; Miyata, K; Suzuki, M; Takeuchi, M; Yamada, T | 1 |
| Ikeda, K; Kobayashi, S; Miyata, K | 1 |
| Araño, P; Bosch, JL; Chapple, CR; De Ridder, D; Kramer, AE; Ridder, AM | 1 |
| Al-Shukri, S; Chapple, CR; Everaert, K; Huang, M; Meffan, P; Rechberger, T; Ridder, A | 1 |
| Hatanaka, T; Ikeda, K; Kobayashi, S; Miyata, K; Ohtake, A; Sasamata, M; Sato, S; Ukai, M | 1 |
| Bosch, JL; Chilman-Blair, K | 1 |
| Krauwinkel, WJ; Mulder, H; Smulders, RA; Uchida, T | 1 |
| Krauwinkel, WJ; Kuipers, ME; Mulder, H; Visser, N | 1 |
| Huang, M; Krauwinkel, WJ; Smulders, RA; Swart, PJ | 1 |
| Cardozo, L; Robinson, D | 2 |
| Hsieh, M; Kershen, RT | 1 |
| Cardozo, L; Drogendijk, TE; Huang, M; Kuzmin, I; Lisec, M; Millard, R; Ridder, AM; van Vierssen Trip, O | 1 |
| Sand, PK | 1 |
| Cardozo, L; Chapple, CR; Haab, F; Kelleher, CJ; Ridder, AM | 1 |
| Cardozo, L; Chapple, C; Haab, F; Ridder, AM | 1 |
| Miyata, K; Oki, T; Sato, S; Yamada, S | 1 |
| Hayashi, A; Noguchi, Y; Ohtake, A; Okutsu, H; Sasamata, M; Sato, S; Suzuki, M; Ukai, M; Yoshino, T; Yuyama, H | 1 |
| Brunton, S; Kuritzky, L | 1 |
| Krauwinkel, WJ; Mulder, H; Smulders, RA; Swart, PJ; Taekema-Roelvink, ME | 1 |
| Bolodeoku, J; Chapple, CR; Drogendijk, T; Martinez-Garcia, R; Selvaggi, L; Toozs-Hobson, P; Warnack, W; Wright, DM | 1 |
| Abrams, P; Swift, S | 1 |
| Oehlke, KJ | 1 |
| Krivoborodov, GG; Mazo, EB | 1 |
| Ikeda, K; Naito, R; Okamoto, Y; Takeuchi, M; Toyoshima, A; Yonetoku, Y | 1 |
| Dmochowski, RR; Staskin, DR; Wein, AJ | 1 |
| Cardozo, L; Kelleher, C; Kobashi, K; Lucente, V | 1 |
| Krauwinkel, WJ; Kuipers, ME; Smulders, RA; Swart, PJ; Taekema-Roelvink, ME; Visser, N | 1 |
| Jonas, U; Rackley, RR | 1 |
| Simpson, D; Wagstaff, AJ | 1 |
| Serels, S | 1 |
| Hashim, H | 1 |
| Halaska, M; Millard, RJ | 1 |
| Miyata, K | 1 |
| Payne, CK | 1 |
| Hussar, DA | 1 |
| MacDiarmid, SA; Staskin, DR | 1 |
| Appell, RA; McCrery, RJ; Smith, PP | 1 |
| Cardozo, L; Castro-Diaz, D; Gittelman, M; Huang, M; Ridder, A | 1 |
| Staskin, DR; Te, AE | 1 |
| Sieber, P; Wagg, A; Wyndaele, JJ | 1 |
| Goepel, M | 1 |
| Oki, T; Takeuchi, C; Yamada, S | 1 |
| Krauwinkel, WJ; Kuipers, ME; Smulders, RA | 1 |
| Krauwinkel, WJ; Smith, NN; Smulders, RA; Swart, PJ | 1 |
| Cardozo, L; Chapple, CR; Govier, FE; Steers, WD | 1 |
| Brubaker, L; Chapple, C; Coyne, KS; Kopp, Z | 1 |
| Kreder, KJ | 1 |
| Hegde, SS; Michel, MC | 1 |
| Maniscalco, M; Singh-Franco, D; Torres-Colón, R; Wolowich, WR | 1 |
| Drinka, PJ | 1 |
| Chapple, CR | 1 |
| Brubaker, L; FitzGerald, MP | 1 |
| Ikeda, K; Miyata, K; Ohtake, A; Sasamata, M; Sato, S | 1 |
| Hoon, T; Krauwinkel, W; Kuipers, M; Smulders, R | 1 |
| Hatanaka, T; Miyata, K; Noguchi, Y; Ohtake, A; Okutsu, H; Saitoh, C; Sasamata, M; Sato, S; Suzuki, M; Ukai, M; Yuyama, H | 1 |
| Colaço, J; Gonçalves, V; Metello, J; Nogueira, B; Retto, H; Torgal, M; Vieira, A | 1 |
| Andoh, M; Garely, AD; Kaufman, JM; Sand, PK; Smith, N | 1 |
| Kelleher, C; Payne, CK | 1 |
| Hoon, TJ; Krauwinkel, WJ; Smith, NN; Smulders, RA | 1 |
| Combest, W; Kosier, JH; Newton, M | 1 |
| Cardozo, L; Cartwright, R; Robinson, D; Vella, M | 1 |
| Adekunle, R; Bilal, S; Fishwick, K; Khunda, A | 1 |
| Garely, AD; Lucente, V; Smith, N; Vapnek, J | 1 |
| Chapple, C | 1 |
| Burks, D; Garely, AD; Mallett, V; Smith, N | 1 |
| Bertozzi, R; Cipriani, S; Colli, E; Meschia, M; Montorsi, F; Olivieri, L; Parazzini, F | 1 |
| Bolodeoku, J; Chapple, CR; Fianu-Jonsson, A; Indig, M; Khullar, V; Mistry, A; Rosa, J; Scarpa, RM; Wright, DM | 1 |
| Colli, E; Digesu, GA; Olivieri, L | 1 |
| Chugh, A; Gupta, JB; Hegde, LG; Kumar, N; Meru, AV; Naruganahalli, KS; Ray, A; Sinha, S | 1 |
| Gotoh, M; Ishizuka, O; Itoh, N; Kakizaki, H; Marui, E; Okada, H; Ozono, S; Seki, N; Sugiyama, T; Yamaguchi, O; Yokota, T; Yoshida, M | 1 |
| Cardozo, L; Drogendijk, TE; Huang, AM; Kuzmin, I; Lisec, M; Milard, R; Van Vierssen Trip, O | 1 |
| Aoki, T; Iwatsubo, T; Kamimura, H; Soeishi, Y; Yanagihara, T | 1 |
| Capo', JP; Fakhoury, A; Forero-Schwanhaeuser, S; Laramée, C; Lucente, V | 1 |
| Hilas, O; Lam, S | 1 |
| Noguchi, Y; Ohtake, A; Okutsu, H; Sasamata, M; Sato, S; Suzuki, M | 1 |
| Gach, JE; Shalders, K | 1 |
| Marshall, T; Noe, L; Rasouliyan, L; Seifeldin, R; Zinner, N | 1 |
| Inadome, A; Maeda, Y; Masunaga, K; Murakami, S; Satoji, Y; Sugiyama, Y; Ueda, S; Yoshida, M | 1 |
| Feldman, LS; Pemmaraju, N | 1 |
| de la Rosette, JJ; Michel, MC; Vogel, M; Wetterauer, U | 1 |
| Bolodeoku, J; Khullar, V; Mundy, A; Odeyemi, I; Speakman, M | 1 |
| Widhalm, S | 1 |
| Capo, JP; Forero-Schwanhaeuser, S; Pelman, RS | 1 |
| Costa, AM; Galatioto, GP; Gravina, GL; Martella, O; Ronchi, P; Vicentini, C | 1 |
| Al, MJ; Hakkaart, L; Phillips, R; Verboom, P | 1 |
| Asajima, H; Matsushima, S; Saito, N; Saito, T; Sekiguchi, Y | 1 |
| Arañó, P; Bolodeoku, J; Cardozo, L; Dewilde, L; Drogendijk, T; Hessdörfer, E; Milani, R; Slack, M; Wright, M | 1 |
| Andoh, M; Fakhoury, A; Forero-Schwanhaeuser, S; Karram, MM; Serels, SR; Toglia, MR | 1 |
| Jangid, AG; Mistri, HN; Pudage, A; Rathod, DM; Shrivastav, PS | 1 |
| Capo', JP; Chancellor, MB; Forero-Schwanhaeuser, S; Karram, M; Kobashi, K; Laramée, C; Nandy, I; Seifeldin, R; Siami, P; Snyder, JA; Whitmore, K; Zinner, N | 1 |
| Burcher, E; Chandran, JJ; Christopoulos, A; Mansfield, KJ; Millard, RJ; Mitchelson, FJ; Vaux, KJ | 1 |
| Choo, MS; Jung, HC; Kim, HJ; Kim, JC; Kim, YH; Lee, JB; Lee, JG; Lee, JZ; Lee, KS; Na, YG; Paick, JS; Seo, JT | 1 |
| Fabisovský, M; Havránek, O; Krhut, J; Míka, D; Valis, P | 1 |
| Schaefer, W | 1 |
| Ballarín, M; Balsa, D; Cabellos, J; Davalillo, S; Fernández, A; Lagunas, C; Pérez-Del-Pulgar, S; Salcedo, C | 1 |
| Duggan, P; Wong, C | 1 |
| Hoffstetter, S; Leong, FC | 1 |
| Forero-Schwanhaeuser, S; Siami, P; Swift, SE | 1 |
| Axelsen, S; Kulseng-Hansen, S; Mattiasson, A; Milsom, I; Nilsson, CG; Wickstrøm, J | 1 |
| Brenes, FJ; Chapple, CR; Rosenberg, MT | 1 |
| Andoh, M; Dmochowski, R; Forero-Schwanhaeuser, S; Sand, PK; Steers, WD | 1 |
| Fujino, T; Ito, Y; Matsui, M; Noguchi, Y; Ohtake, A; Oyunzul, L; Sasamata, M; Suzuki, M; Yamada, S; Yoshida, A; Yuyama, H | 1 |
| Iannazzo, S; Pradelli, L | 1 |
| Doroshyenko, O; Fuhr, U | 1 |
| Altman, D; Falconer, C; Granath, F; Mattiasson, A | 1 |
| De Caestecker, K; De Pooter, J; Dehoorne, J; Hoebeke, P; Raes, A; Van Laecke, E; Vande Walle, J | 1 |
| Bolodeoku, J; Edgar, C; Tretter, RN; Wesnes, KA | 1 |
| Bolodeoku, J; Masala, A; Mattiasson, A; Morton, R | 1 |
| Andoh, M; Forero-Schwanhaeuser, S; Karram, MM; Laramée, C; Nandy, IM; Seifeldin, R; Serels, SR; Toglia, MR | 1 |
| Fakhoury, A; Fincher, R; He, W; Kaplan, SA; McCammon, K | 2 |
| Nakade, S; Ogawa, M; Ohno, T | 1 |
| Forero-Schwanhaeuser, S; He, W; Marshall, TS; Mitcheson, HD; Samuels, TA; Vardy, MD; Wegenke, JD | 1 |
| Andoh, M; Forero-Schwanhaeuser, S; Gittelman, M; Goldfischer, ER; Kaplan, SA; Steers, WD | 1 |
| Marshall, T; Noe, L; Rasouliyan, L; Runken, MC; Seifeldin, R; Zinner, N | 1 |
| Cardozo, L; Sidhu, M; Thorpe, A; Warner, J | 1 |
| Miyata, K; Ohtake, A; Sasamata, M; Sato, S | 1 |
| Wyndaele, JJ | 1 |
| Barkin, J; Carlson, K; Drutz, H; Egerdie, B; Gajewski, JB; Herschorn, S; Paradiso-Hardy, F; Pommerville, P; Radomski, S; Schulz, J; Stothers, L | 1 |
| Andoh, M; Appell, RA; Fakhoury, A; Hussain, IF; Ostergard, DR; Toglia, MR | 1 |
| Santos, JC; Telo, ER | 1 |
| Masumori, N; Tanaka, Y; Tsukamoto, T | 1 |
| Herschorn, S; Piwko, C; Vicente, C | 1 |
| Forero-Schwanhaeuser, S; He, W; Serels, SR; Toglia, MR | 1 |
| Fujino, T; Kageyama, A; Nozawa, Y; Yamada, S; Yoshida, A | 1 |
| Bolduc, S; Hamel, M; Lamontagne, P; Lebel, S; Moore, K; Nadeau, G | 1 |
| Chernev, T; Dimitrov, R; Doganov, N; Popov, E; Slavov, Ch; Slavov, S | 1 |
| Grinta, R; Vecchioli-Scaldazza, C | 1 |
| Chang, TC; Ho, CH; Huang, KH; Lin, HH; Liu, SP; Yu, HJ | 1 |
| Krishna, SR; Rao, BM; Rao, NS | 1 |
| Klíma, J; Macek, J; Ptáček, P | 1 |
| Barkin, J; Carlson, K; Corcos, J; Drutz, H; Egerdie, B; Gajewski, J; Herschorn, S; Hirshberg, E; Pommerville, P; Radomski, S; Schulz, J; Stothers, L | 1 |
| Crosby, RD; Marshall, TS; Mathias, SD | 1 |
| Capo', JP; Forero-Schwanhaeuser, S; He, W; Lucente, V | 1 |
| de la Rosette, JJ; Michel, MC; Oelke, M; Vogel, M | 1 |
| Jakobsen, SM; Kersten, H; Molden, E | 1 |
| Bungay, PJ; Callegari, E; Fenner, KS; Kay, GG; Kempshall, S; LaPerle, JL; Malhotra, B; Michel, MC; Webster, R | 1 |
| Basu, M; Duckett, J | 1 |
| Schröder, A; Thüroff, JW | 1 |
| Chang, TC; Chen, CH; Hsiao, SM; Lin, HH; Wu, WY; Yu, HJ | 1 |
| Gotoh, M; Ishizuka, O; Itoh, N; Kakizaki, H; Okada, H; Ozono, S; Seki, N; Sugiyama, T; Yamada, S; Yamaguchi, O; Yokota, T; Yokoyama, O; Yoshida, M | 1 |
| Bergamasco, L; Gualà, L; Maselli, G; Pace, G; Silvestri, V; Vicentini, C | 1 |
| Kalchthaler, M; Mühlich, S; Rothe, P | 2 |
| Gotoh, M; Homma, Y; Kakizaki, H; Nishizawa, O; Seki, N; Takeda, M; Yamaguchi, O; Yokoyama, O; Yoshida, M | 1 |
| Fukuhara, S; Matsuoka, Y; Miyagawa, Y; Nakayama, J; Nonomura, N; Takao, T; Tsujimura, A; Yamamoto, K | 1 |
| Kuo, HC; Lin, H; Liu, HT | 1 |
| Abrams, P; Chapple, CR; Jünemann, KP; Sharpe, S | 1 |
| Brubaker, L; Durazo-Arivzu, RA; Fitzgerald, MP; Kenton, K; Lowenstein, L; Mueller, ER; Sabo, E | 1 |
| Akino, H; Aoki, Y; Ito, H; Nagase, K; Tanase, K; Yokoyama, O | 1 |
| Chess-Williams, R; Moro, C; Uchiyama, J | 1 |
| Ishida, H; Omoto, K; Shimizu, T; Tanabe, K; Tsunoyama, K | 1 |
| Cody, JD; Ellis, G; Hay-Smith, EJ; Herbison, GP; Madhuvrata, P | 1 |
| Han, P; Liu, L; Luo, D; Shen, H; Wei, Q | 1 |
| Cho, KS; Chung, JH; Ha, US; Ham, WS; Han, JH; Kang, DH; Lee, JY; Lee, SH; Lee, SW; Park, J; Yoo, TK | 1 |
| Kane, RL; Ramakrishnan, R; Sainfort, F; Shamliyan, T; Wyman, JF | 1 |
| Banović, M; But, I; Goldstajn, MS; Oresković, S | 1 |
| Cummings, J; Fakhoury, A; He, W; Kaplan, SA; Koltun, WD; Schneider, T | 1 |
| Alessandri, F; Candiani, M; Ferrero, S; Leone Roberti Maggiore, U; Origoni, M; Remorgida, V; Salvatore, S; Venturini, PL | 1 |
| Andersson, KE; Gratzke, C | 1 |
| Ammann, LP; Bukofzer, S; Haas, GP; He, W; Janning, SW; Zinner, NR | 1 |
| Brubaker, L; Khandwala, S; Lowder, J; Meikle, SF; Menefee, SA; Nolen, TL; Nygaard, I; Paraiso, MF; Richter, HE; Schaffer, J; Sirls, L; Spino, C; Visco, AG; Wallace, D | 1 |
| Bharucha, AE; Guan, Z; Hiro, S; Isowa, H | 1 |
| Fukumoto, K; Hara, R; Koide, T; Miyaji, Y; Nagai, A; Yokoyama, T | 1 |
| Krebs, J; Pannek, J | 1 |
| Amarenco, G; Cardozo, L; Compion, G; Drogendijk, T; Mikulas, J; Pushkar, D; Wright, M | 1 |
| Jiang, XZ; Xu, C; Xu, ZS; Zhang, NZ; Zhao, HF | 1 |
| Compion, G; Dale, M; Stow, B; Tretter, R; Wagg, A | 2 |
| But, I; Goldstajn, MS; Oresković, S | 1 |
| Cornu, JN | 1 |
| Namiki, N; Uchida, S; Yoshita, T | 1 |
| Hsiao, SM; Kuo, HC; Lin, HH | 1 |
| Chang, HC; Chen, J; Huang, KH; Lee, YJ; Yang, HJ; Yang, TK | 1 |
| Angulo, JC; Garcia-Hernandez, A; Haab, F; Katona, F; Klaver, M; Oelke, M; Traudtner, K; Van Kerrebroeck, P; Vik, V | 2 |
| Berouz, A; Ferrara, V; Giannubilo, W; Morosetti, C; Vecchioli-Scaldazza, C | 1 |
| Apostolidis, A | 1 |
| Haraguchi, T; Miyazaki, A; Uchida, T; Yoshida, M | 1 |
| Mauseth, SA; Skurtveit, S; Spigset, O | 1 |
| Abrams, P; Hart, WM; Munro, V; Nazir, J; Retsa, P | 1 |
| Chapple, C; Drake, MJ; Drogendijk, T; Klaver, M; Sokol, R; Speakman, M; Traudtner, K; van Kerrebroeck, P | 1 |
| Arora, R; Arora, V; Dey, S; Kandhwal, K; Khuroo, AH; Madan, S; Monif, T; Nazarudheen, S; Reyar, S | 1 |
| Braga, A; Cattoni, E; Cromi, A; Ghezzi, F; Salvatore, S; Serati, M; Siesto, G; Sorice, P; Uccella, S | 1 |
| Byun, SS; Kim, KH; Lee, JY; Lee, SH; Lee, SJ | 1 |
| Akino, H; Fujiuchi, Y; Fuse, H; Kitagawa, Y; Miyazawa, K; Namiki, M; Suzuki, K; Yokoyama, O | 1 |
| Arumi, D; Lizarraga, I; Miranda, P; Rejas, J; Sánchez-Ballester, F | 1 |
| Bratuš, D; But, I; Hlebič, G; Orešković, S; Šprem-Goldštajn, M | 1 |
| Betz, D; Burger, M; Hampel, C; Vogel, M | 1 |
| Aguado-Jodar, A; Ibáñez-Nolla, J; Kvasz, M; Navarro-Artieda, R; Rejas, J; Ruiz-Torrejón, A; Sicras-Mainar, A | 1 |
| Braga, A; Ghezzi, F; Salvatore, S; Serati, M; Siesto, G; Sorice, P | 1 |
| Gotoh, M; Kobayashi, T; Sogabe, K | 1 |
| Alexandre, L; Audet, A; Behr-Roussel, D; Bernabé, J; Caisey, S; Charon, C; Giuliano, F; Kergoat, M; Oger-Roussel, S | 1 |
| Walton, A | 1 |
| An, R; Guan, Z; Guo, H; He, D; Huang, J; Huang, Y; Kong, C; Li, H; Liao, L; Liu, M; Shen, Z; Song, B; Song, X; Sun, Y; Wang, D; Wang, J; Wang, X; Wen, J; Xiao, J; Yang, Y; Ye, Z; Zeng, P; Zhang, X; Zhao, X; Zheng, S | 1 |
| Guo, KC; Huo, LZ; Jing, HG; Luan, XH; Shi, BK; Wang, TC; Yuan, SX | 1 |
| Uchida, T | 1 |
| Hart, WM; Nazir, J | 1 |
| Gao, ZW; Li, HB; Ren, XQ; Shang, YF; Shao, CS; Xiao, F; Xin, SY; Zhang, JG; Zhang, W | 1 |
| Cao, Z; Guo, F; Pan, A; Peng, S; Sun, Y; Wang, H; Wang, L; Wei, R; Xu, C; Zhang, C; Zhang, Z | 1 |
| Arslan, U; Dolen, I; Hekimoglu, E; Petricli, IS; Sekeroglu, MA; Tasci, Y | 1 |
| Ahlering, TE; Liss, MA; Morales, B; Skarecky, D | 1 |
| Adiloğlu, AK; Arslan, H; Aydın, A; Aydoğmuş, Y; Şahin, H; Sunay, M | 1 |
| Kosilov, KV; Kosilova, LV; Krasnykh, MA; Loparev, SA | 1 |
| Chen, Y; Liu, B; Liu, Z; Mo, Q; Wang, Y; Wu, J; Xu, H | 1 |
| Andersson, KE | 1 |
| Ivanovskaya, MA; Kosilov, KV; Kosilova, LV; Loparev, SA | 2 |
| Doo, SW; Kim, JH; Lee, SW; Yang, HJ; Yang, WJ; Yun, JH | 1 |
| Hyun, JS; Kim, SW; Ko, K; Lee, SW; Lee, WK; Moon, du G; Moon, KH; Park, JK; Park, K; Park, NC; Son, HC; Yang, DY | 1 |
| Ahlering, TE; Albala, DM; Belkoff, LH; Bianco, FJ; Bradt, JS; Haas, GP; He, W; Miles, BJ; Peabody, JO | 1 |
| Chung, BH; Hong, S; Kim, CS; Kim, DK; Kim, JC; Lee, JG; Lee, KS; Lee, YS; Park, CH; Park, JK | 1 |
| Blak, B; Hakimi, Z; Johnson, M; Nazir, J; Odeyemi, IA | 1 |
| Li, J; Li, P; Liu, B; Wang, Y; Wu, Y | 1 |
| Choo, MS; Han, JY; Kim, DY; Kwon, DD; Lee, JG; Lee, JZ; Lee, KS; Na, YG; Park, CH; Park, WH | 1 |
| Crosby, RD; Drogendijk, T; Hakimi, Z; Klaver, M; Mathias, SD; Nazir, J; Odeyemi, IA | 1 |
| Cheon, SY; Cho, SY; Choi, JB; Choo, MS; Chun, JY; Kim, JC; Kim, JH; Lee, KS; Oh, SJ; Park, J; Seo, JT; Song, M | 1 |
| Abiraman, K; Chen, GD; Ekwegbalu, EC; Khaku, ZM; Li, JX; O'Bara, MA; Pol, SU; Salvi, RJ; Sim, FJ; Thorn, D; Vedia, BH; Wang, J | 1 |
| Borodulina, IV; Kadykov, AS; Kravchenko, MA; Popov, SV; Shvarts, PG; Vinarov, AZ | 1 |
| Ahn, H; Choi, SK; Choo, MS; Huh, KO; Kim, J; Lee, SM; Park, S; Shim, M; Song, C | 1 |
| Hagiwara, M; Hasegawa, M; Ishioka, K; Kikuchi, E; Maeda, T; Miyajima, A; Miyazaki, Y; Oya, M; Shinojima, T | 1 |
| Kagan, OF; Kheĭfets, VKh; Sosnovskiĭ, SO | 2 |
| Masumori, N; Tanaka, Y; Tanuma, Y | 1 |
| Cruz, F | 1 |
| Kaplan, SA | 1 |
| Ablove, T; Bell, LN; Chappell, RJ; Liang, H; Toklu, HZ; Yale, SH | 1 |
46 review(s) available for solifenacin succinate and quinuclidines
| Article | Year |
|---|---|
Solifenacin: treatment of overactive bladder.
Topics: Animals; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Humans; Muscarinic Antagonists; Quinuclidines; Receptor, Muscarinic M3; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Neurogenic | 2004 |
The emerging role of solifenacin in the treatment of overactive bladder.
Topics: Clinical Trials as Topic; Humans; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Incontinence | 2004 |
Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine.
Topics: Benzilates; Benzofurans; Clinical Trials as Topic; Duloxetine Hydrochloride; Humans; Muscarinic Antagonists; Nortropanes; Pyrrolidines; Quinuclidines; Selective Serotonin Reuptake Inhibitors; Solifenacin Succinate; Tetrahydroisoquinolines; Thiophenes; Urinary Incontinence | 2004 |
Elevating our therapeutic expectations in overactive bladder.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Constipation; Cresols; Delayed-Action Preparations; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Incontinence; Vision Disorders; Xerostomia | 2004 |
Improved quality of life in patients with overactive bladder symptoms treated with solifenacin.
Topics: Adult; Double-Blind Method; Female; Humans; Interpersonal Relations; Male; Multicenter Studies as Topic; Muscarinic Antagonists; Quality of Life; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder Diseases; Urinary Incontinence | 2005 |
Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg.
Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Humans; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder Diseases; Urination Disorders | 2005 |
Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis.
Topics: Adult; Clinical Trials, Phase III as Topic; Female; Humans; Male; Middle Aged; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Incontinence | 2005 |
[Neurological aspect of the hyperactive urinary bladder syndrome].
Topics: Benzilates; Brain; Brain Diseases; Cerebrovascular Circulation; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Parkinson Disease; Positron-Emission Tomography; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Neurogenic | 2005 |
Solifenacin in the management of the overactive bladder syndrome.
Topics: Clinical Trials as Topic; Humans; Quinuclidines; Receptor, Muscarinic M3; Solifenacin Succinate; Syndrome; Tetrahydroisoquinolines; Urinary Bladder Diseases; Urinary Incontinence; Urination Disorders | 2005 |
Solifenacin in overactive bladder syndrome.
Topics: Humans; Muscarinic Antagonists; Quality of Life; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Syndrome; Tetrahydroisoquinolines; Urinary Incontinence | 2005 |
Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis.
Topics: Adult; Aged; Aged, 80 and over; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Placebos; Population; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Incontinence | 2006 |
[Drug discovery in the fields of urology: tamsulosin and solifenacin].
Topics: Adrenergic alpha-Antagonists; Animals; Biological Availability; Cholinergic Antagonists; Delayed-Action Preparations; Drug Design; Humans; Male; Quinuclidines; Receptor, Muscarinic M3; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder; Urination Disorders | 2005 |
Solifenacin in overactive bladder syndrome.
Topics: Animals; Antimutagenic Agents; Clinical Trials as Topic; Humans; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Incontinence | 2006 |
Using anticholinergics to treat overactive bladder: the issue of treatment tolerability.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Nortropanes; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Incontinence | 2006 |
The emergence of new drugs for overactive bladder.
Topics: Acetylcholine; Amines; Animals; Anticonvulsants; Benzhydryl Compounds; Cresols; Cyclohexanecarboxylic Acids; Drug Evaluation, Preclinical; Gabapentin; gamma-Aminobutyric Acid; Humans; Mandelic Acids; Muscarinic Antagonists; Muscle, Smooth; Phenylpropanolamine; Product Surveillance, Postmarketing; Quinuclidines; Randomized Controlled Trials as Topic; Receptor, Muscarinic M3; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder; Urinary Incontinence | 2006 |
Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Topics: Aged; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Female; Humans; Male; Muscarinic Antagonists; Quinuclidines; Randomized Controlled Trials as Topic; Retrospective Studies; Solifenacin Succinate; Syndrome; Tetrahydroisoquinolines; Urinary Incontinence | 2006 |
Solifenacin significantly improves all symptoms of overactive bladder syndrome.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Muscarinic Antagonists; Quality of Life; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2006 |
Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Cresols; Health Status; Humans; Mandelic Acids; Muscarinic Antagonists; Patient Compliance; Patient Satisfaction; Phenylpropanolamine; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Neurogenic; Urinary Incontinence, Stress | 2006 |
Solifenacin.
Topics: Clinical Trials as Topic; Humans; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2006 |
Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Parasympatholytics; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2006 |
Solifenacin succinate for the treatment of symptoms of overactive bladder.
Topics: Clinical Trials as Topic; Humans; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics | 2006 |
Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder.
Topics: Dose-Response Relationship, Drug; Female; Humans; Male; Molecular Structure; Muscarinic Antagonists; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2006 |
[Pharmacological and clinical profile of solifenacin succinate (Vesicare) developed as a new therapeutic agent for overactive bladder].
Topics: Animals; Clinical Trials as Topic; Humans; Muscarinic Antagonists; Muscle, Smooth; Quinuclidines; Receptors, Muscarinic; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder; Urinary Bladder, Overactive; Urination | 2006 |
Redefining response in overactive bladder syndrome.
Topics: Double-Blind Method; Humans; Multicenter Studies as Topic; Muscarinic Antagonists; Quality of Life; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Surveys and Questionnaires; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2007 |
New developments in the treatment of urinary incontinence.
Topics: Administration, Cutaneous; Adrenergic Uptake Inhibitors; Benzofurans; Drug Therapy, Combination; Duloxetine Hydrochloride; Humans; Mandelic Acids; Muscarinic Antagonists; Pyrrolidines; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Thiophenes; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Stress | 2006 |
Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials.
Topics: Benzhydryl Compounds; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Urination | 2007 |
Update on drugs for overactive bladder syndrome.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2007 |
Overactive bladder treatments in early phase clinical trials.
Topics: Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Models, Animal; Drugs, Investigational; Guanidines; Humans; Mice; Muscarinic Antagonists; Quinuclidines; Receptors, Muscarinic; Sensitivity and Specificity; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2007 |
Pharmacologic management of overactive bladder.
Topics: Benzhydryl Compounds; Benzofurans; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2007 |
Solifenacin at 3 years: a review of efficacy and safety.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2008 |
Solifenacin succinate for the treatment of overactive bladder.
Topics: Animals; Clinical Trials as Topic; Female; Humans; Male; Muscarinic Antagonists; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2009 |
Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome.
Topics: Benzofurans; Drug Administration Schedule; Humans; Mandelic Acids; Multicenter Studies as Topic; Muscarinic Antagonists; Patient Satisfaction; Pyrrolidines; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2009 |
Clinical pharmacokinetics and pharmacodynamics of solifenacin.
Topics: Animals; Clinical Trials as Topic; Humans; Protein Binding; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Incontinence | 2009 |
The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgen
Topics: Adenosine Triphosphate; Afferent Pathways; Animals; Disease Models, Animal; Humans; Muscarinic Antagonists; Muscle Contraction; Quinuclidines; Rats; Receptors, Muscarinic; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2010 |
Solifenacin: scientific evidence in the treatment of overactive bladder.
Topics: Clinical Trials as Topic; Humans; Muscarinic Antagonists; Quality of Life; Quinuclidines; Retrospective Studies; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2010 |
New strategies for medical management of overactive bladder in children.
Topics: Benzhydryl Compounds; Benzilates; Botulinum Toxins; Child; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Quinuclidines; Receptors, Muscarinic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Urination | 2010 |
Urinary urgency: a review of its assessment as the key symptom of the overactive bladder syndrome.
Topics: Endpoint Determination; Female; Humans; Male; Muscarinic Antagonists; Outcome Assessment, Health Care; Prevalence; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Young Adult | 2012 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropanolamine; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Incontinence | 2012 |
Solifenacin for overactive bladder: a systematic review and meta-analysis.
Topics: Benzhydryl Compounds; Cresols; Dose-Response Relationship, Drug; Humans; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2012 |
Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Comparative Effectiveness Research; Cresols; Female; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Pyrrolidines; Quality of Life; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Incontinence | 2012 |
Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Chronic Disease; Cresols; Drug Combinations; Female; Humans; Imidazoles; Mandelic Acids; Muscarinic Antagonists; Nocturia; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Incontinence | 2012 |
[Safety of solifenacin and tolterodine in the treatment of overactive bladder: a meta-analysis].
Topics: Benzhydryl Compounds; Cresols; Humans; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2012 |
[Comprehensive evaluation of palatability for commercial medicine by taste sensing system].
Topics: Administration, Oral; Amino Acids; Humans; Quinuclidines; Solifenacin Succinate; Tablets; Taste; Tetrahydroisoquinolines | 2014 |
The use of pharmacotherapy for male patients with urgency and stress incontinence.
Topics: 5-alpha Reductase Inhibitors; Acetanilides; Adrenergic alpha-1 Receptor Antagonists; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Thiazoles; Urinary Bladder, Overactive; Urinary Incontinence, Stress; Urinary Incontinence, Urge; Urological Agents | 2014 |
[Comparisons of therapeutic efficacy and safety of solifenacin versus tolterodine in patients with overactive bladder: a meta-analysis of outcomes].
Topics: Benzhydryl Compounds; Constipation; Cresols; Humans; Phenylpropanolamine; Quinuclidines; Safety; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Xerostomia | 2014 |
[Current pharmacotherapy of overactive bladder in neurological patients].
Topics: Humans; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urination; Urological Agents | 2014 |
89 trial(s) available for solifenacin succinate and quinuclidines
| Article | Year |
|---|---|
Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Single-Blind Method; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder Diseases; Urinary Retention; Urination | 2004 |
Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder Diseases; Urination Disorders | 2004 |
Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial.
Topics: Adolescent; Adult; Area Under Curve; Cross-Over Studies; Food; Food-Drug Interactions; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines | 2004 |
Solifenacin demonstrates high absolute bioavailability in healthy men.
Topics: Adult; Biological Availability; Cross-Over Studies; Humans; Male; Metabolic Clearance Rate; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines | 2004 |
Pharmacokinetics and safety of solifenacin succinate in healthy young men.
Topics: Adolescent; Adult; Area Under Curve; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Half-Life; Heart Rate; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Salivation; Solifenacin Succinate; Tetrahydroisoquinolines; Vision, Ocular | 2004 |
Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Humans; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder Diseases; Urinary Incontinence | 2004 |
Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.
Topics: Constipation; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Patient Satisfaction; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Time; Treatment Outcome; Urinary Incontinence; Vision Disorders; Xerostomia | 2005 |
Effect of age on the pharmacokinetics of solifenacin in men and women.
Topics: Adult; Age Factors; Aged; Area Under Curve; Blood Proteins; Cross-Over Studies; Female; Half-Life; Humans; Male; Middle Aged; Muscarinic Antagonists; Protein Binding; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines | 2005 |
A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.
Topics: Analysis of Variance; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prospective Studies; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Incontinence | 2005 |
Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence.
Topics: Aged; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2006 |
Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin.
Topics: Adult; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Muscarinic Antagonists; Population; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2006 |
Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence.
Topics: Adolescent; Adult; Aged; Cholinergic Antagonists; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Incontinence; Urodynamics | 2006 |
Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects.
Topics: Administration, Oral; Adult; Anticoagulants; Area Under Curve; Cardiotonic Agents; Digoxin; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Warfarin | 2006 |
Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers.
Topics: Adolescent; Adult; Antifungal Agents; Area Under Curve; Cross-Over Studies; Drug Interactions; Female; Humans; Ketoconazole; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines | 2006 |
Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms.
Topics: Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Nocturia; Polyuria; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2007 |
Open-label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Area Under Curve; Female; Follow-Up Studies; Half-Life; Humans; Liver Diseases; Male; Metabolic Clearance Rate; Middle Aged; Muscarinic Antagonists; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Time Factors | 2006 |
Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride.
Topics: Aged; Analgesics; Benzilates; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Middle Aged; Muscarinic Antagonists; Nortropanes; Prospective Studies; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2007 |
Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; United States; Urinary Bladder, Overactive | 2006 |
Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Constipation; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Visual Acuity; Xerostomia | 2007 |
Solifenacin treatment for overactive bladder in black patients: patient-reported symptom bother and health-related quality of life outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Black or African American; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2007 |
Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg.
Topics: Aged; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Safety; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Stress; Urination | 2007 |
Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
Topics: Adult; Aged; Benzilates; Constipation; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Xerostomia | 2007 |
[A placebo-controlled, double-blind, randomized trial of single daily dose of anti-muscarinic drug solifenacin succinate in patients with overactive bladder].
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urination | 2007 |
Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Attitude to Health; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2008 |
Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER.
Topics: Activities of Daily Living; Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Female; Health Services; Humans; Male; Middle Aged; Muscarinic Antagonists; Outcome Assessment, Health Care; Patient Acceptance of Health Care; Phenylpropanolamine; Quality of Life; Quinuclidines; Solifenacin Succinate; Surveys and Questionnaires; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2008 |
A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Cresols; Double-Blind Method; Humans; Markov Chains; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2008 |
Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity.
Topics: Aged; Humans; Male; Middle Aged; Muscarinic Antagonists; Muscle Contraction; Perception; Prospective Studies; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics | 2009 |
Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urination Disorders; Urodynamics | 2008 |
Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial.
Topics: Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Time Factors; Urinary Bladder, Overactive; Urination | 2009 |
Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Topics: Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2008 |
Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Nocturia; Patient Satisfaction; Prospective Studies; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urinary Retention | 2008 |
[Efficacy and safety of solifenacin in daily clinical practice--clinical study phase IV].
Topics: Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2008 |
Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: a pilot study.
Topics: Adult; Aged; Cholinergic Antagonists; Female; Humans; Mandelic Acids; Middle Aged; Nocturia; Pilot Projects; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Failure; Urinary Bladder, Overactive | 2009 |
Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.
Topics: Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Surveys and Questionnaires; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2009 |
Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg.
Topics: Aged; Attention; Cognition; Cognition Disorders; Cross-Over Studies; Executive Function; Female; Humans; Hypnotics and Sedatives; Learning; Male; Mandelic Acids; Memory; Memory, Short-Term; Muscarinic Antagonists; Neuropsychological Tests; Parasympatholytics; Pilot Projects; Quinuclidines; Reaction Time; Risk; Sample Size; Solifenacin Succinate; Tetrahydroisoquinolines | 2009 |
Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Behavior Therapy; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quinuclidines; Single-Blind Method; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Young Adult | 2010 |
Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial.
Topics: Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2009 |
Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2009 |
Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Young Adult | 2009 |
Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes.
Topics: Aged; Humans; Male; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urination | 2010 |
Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
Topics: Adult; Aged; Aged, 80 and over; Canada; Chi-Square Distribution; Double-Blind Method; Drug Administration Schedule; Female; Humans; Incidence; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Surveys and Questionnaires; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Xerostomia | 2010 |
Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status.
Topics: Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urinary Incontinence | 2010 |
Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder.
Topics: Canada; Cost-Benefit Analysis; Female; Humans; Male; Mandelic Acids; Markov Chains; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2010 |
Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Medical Records; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Placebos; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urination; Young Adult | 2010 |
Prospective open label study of solifenacin for overactive bladder in children.
Topics: Child; Female; Humans; Male; Muscarinic Antagonists; Prospective Studies; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Urinary Incontinence | 2010 |
Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prospective Studies; Quinuclidines; Solifenacin Succinate; Taiwan; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination | 2010 |
Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (≤ 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Canada; Dosage Forms; Double-Blind Method; Female; Humans; Male; Meta-Analysis as Topic; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Young Adult | 2011 |
Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study.
Topics: Analysis of Variance; Female; Humans; Lower Urinary Tract Symptoms; Male; Muscarinic Antagonists; Patient Satisfaction; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2011 |
Which single-item measures of overactive bladder symptom treatment correlate best with patient satisfaction?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Health Status; Humans; Male; Middle Aged; Muscarinic Antagonists; Outcome Assessment, Health Care; Patient Satisfaction; Quality of Life; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Surveys and Questionnaires; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2011 |
Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome.
Topics: Adult; Aged; Benzhydryl Compounds; Cresols; Female; Humans; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Urodynamics | 2011 |
Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary.
Topics: Aged; Double-Blind Method; Female; Humans; Japan; Male; Medical Records; Middle Aged; Muscarinic Antagonists; Nocturia; Quinuclidines; Sleep; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2011 |
Tadalafil versus solifenacin for persistent storage symptoms after prostate surgery in patients with erectile dysfunction: a prospective randomized study.
Topics: Aged; Carbolines; Erectile Dysfunction; Humans; Male; Middle Aged; Muscarinic Antagonists; Phosphodiesterase 5 Inhibitors; Postoperative Complications; Prospective Studies; Prostatic Hyperplasia; Quinuclidines; Solifenacin Succinate; Surveys and Questionnaires; Tadalafil; Tetrahydroisoquinolines; Therapeutics; Urination Disorders; Urodynamics | 2011 |
[Treatment with solifenacin reduces urinary urgency and improves quality of life. Results of the non-interventional CAP-study].
Topics: Adult; Aged; Cooperative Behavior; Female; Germany; Humans; Interdisciplinary Communication; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urodynamics | 2011 |
Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Prostatism; Quinuclidines; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2011 |
Improvement of urinary dysfunction after kidney transplantation by administration of the antimuscarinic agent--prospective randomized controlled study.
Topics: Adult; Female; Health Surveys; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Muscarinic Antagonists; Postoperative Complications; Prospective Studies; Quality of Life; Quinuclidines; Renal Dialysis; Solifenacin Succinate; Surveys and Questionnaires; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder; Urinary Bladder Diseases | 2012 |
Efficacy and safety of solifenacin to treat overactive bladder symptoms in patients with idiopathic normal pressure hydrocephalus: an open-label, multicenter, prospective study.
Topics: Adult; Female; Humans; Hydrocephalus, Normal Pressure; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quality of Life; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Surveys and Questionnaires; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics; Ventriculoperitoneal Shunt | 2012 |
The efficacy and safety of solifenacin in patients with overactive bladder syndrome.
Topics: Aged; Female; Humans; Middle Aged; Muscarinic Antagonists; Placebos; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2012 |
Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Analysis of Variance; Double-Blind Method; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Muscarinic Antagonists; Pressure; Quinuclidines; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder Neck Obstruction; Urodynamics | 2013 |
Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.
Topics: Aged; Benzilates; Botulinum Toxins, Type A; Cholinergic Antagonists; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Linear Models; Middle Aged; Nortropanes; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Incontinence, Urge; Urinary Retention; Urinary Tract Infections; Xerostomia | 2012 |
Differential effects of selective and non-selective muscarinic antagonists on gastrointestinal transit and bowel function in healthy women.
Topics: Adolescent; Adult; Benzhydryl Compounds; Colon; Double-Blind Method; Female; Gastrointestinal Motility; Humans; Intestine, Small; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Young Adult | 2013 |
Long-term safety and efficacy of two different antimuscarinics, imidafenacin and solifenacin, for treatment of overactive bladder: a prospective randomized controlled study.
Topics: Aged; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Xerostomia | 2013 |
Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2013 |
Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).
Topics: Administration, Oral; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urination | 2013 |
Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Analysis of Variance; Attention; Cognition; Cognitive Dysfunction; Cross-Over Studies; Double-Blind Method; Female; Humans; Least-Squares Analysis; Male; Mandelic Acids; Memory; Muscarinic Antagonists; Quinuclidines; Risk Factors; Solifenacin Succinate; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; United Kingdom; Urinary Bladder, Overactive; Urological Agents | 2013 |
Comparison of two selective muscarinic receptor antagonists (solifenacin and darifenacin) in women with overactive bladder--the SOLIDAR study.
Topics: Benzofurans; Female; Humans; Middle Aged; Muscarinic Antagonists; Prospective Studies; Pyrrolidines; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2012 |
Reduction in the volume of water for ingesting orally disintegrating tablets of solifenacin (Vesicare® OD), and the clinical disintegration time of Vesicare® OD after unit-dose packaging.
Topics: Administration, Oral; Cross-Over Studies; Drug Packaging; Female; Humans; Male; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Solubility; Tablets; Tetrahydroisoquinolines; Water; Young Adult | 2013 |
Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy.
Topics: Adult; Aged; Female; Hematuria; Humans; Lithotripsy; Male; Middle Aged; Muscarinic Antagonists; Pain; Prospective Studies; Quinuclidines; Solifenacin Succinate; Stents; Tetrahydroisoquinolines; Ureteral Calculi; Ureteral Obstruction; Ureteroscopy; Urological Agents | 2013 |
Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Drug Dosage Calculations; Drug Therapy, Combination; Europe; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Muscarinic Antagonists; Quality of Life; Quinuclidines; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Urinary Bladder; Urination; Urination Disorders; Urodynamics; Urological Agents | 2013 |
Solifenacin succinate versus percutaneous tibial nerve stimulation in women with overactive bladder syndrome: results of a randomized controlled crossover study.
Topics: Adult; Aged; Aged, 80 and over; Cross-Over Studies; Female; Humans; Middle Aged; Patient Satisfaction; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tibial Nerve; Transcutaneous Electric Nerve Stimulation; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urination; Urological Agents | 2013 |
Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial.
Topics: Absorption; Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Aged; Double-Blind Method; Drug Combinations; Humans; Lower Urinary Tract Symptoms; Male; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Sulfonamides; Tablets; Tamsulosin; Tetrahydroisoquinolines | 2013 |
Combining benefits of an adrenergic and a muscarinic blocker in a single formulation - a pharmacokinetic evaluation.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Humans; Male; Muscarinic Antagonists; Quinazolines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Therapeutic Equivalency; Urological Agents; Young Adult | 2013 |
Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study.
Topics: Adrenergic alpha-Antagonists; Drug Therapy, Combination; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Prostatic Hyperplasia; Quinuclidines; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive | 2014 |
[A combination of solifenacin succinate and naftopidil in the treatment of female overactive bladder].
Topics: Adult; Drug Therapy, Combination; Female; Humans; Middle Aged; Muscarinic Antagonists; Naphthalenes; Piperazines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Young Adult | 2013 |
[Efficacy of combination therapy of tamsulosin and solifenacin for mild and moderate benign prostatic hyperplasia with overactive bladder].
Topics: Aged; Drug Therapy, Combination; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quinuclidines; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2014 |
Solifenacin is able to improve the irritative symptoms after transurethral resection of bladder tumors.
Topics: Cystectomy; Cystitis; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quinuclidines; Remission Induction; Single-Blind Method; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder Diseases; Urinary Bladder Neoplasms; Urinary Bladder, Overactive; Urination Disorders | 2014 |
Phase 1 clinical trial of Vesicare™ (solifenacin) in the treatment of urinary incontinence after radical prostatectomy.
Topics: Aged; Humans; Male; Middle Aged; Muscarinic Antagonists; Pilot Projects; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Quinuclidines; Robotic Surgical Procedures; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Incontinence | 2014 |
Acupuncture versus solifenacin for treatment of overactive bladder and its correlation with urine nerve growth factor levels: a randomized, placebo-controlled clinical trial.
Topics: Acupuncture Therapy; Adolescent; Adult; Biomarkers; Female; Humans; Middle Aged; Muscarinic Antagonists; Nerve Growth Factor; Quality of Life; Quinuclidines; Recovery of Function; Solifenacin Succinate; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Turkey; Urinary Bladder; Urinary Bladder, Overactive; Urination; Urodynamics; Urological Agents; Young Adult | 2014 |
[Treatment of overactive bladder in older women increased doses of antimuscarinic drugs safe and effective alternative to existing methods].
Topics: Aged; Benzhydryl Compounds; Benzilates; Cresols; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Female; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urodynamics | 2014 |
Effect of electroacupuncture versus pelvic floor muscle training plus solifenacin for moderate and severe mixed urinary incontinence in women: a study protocol.
Topics: Adult; Aged; Clinical Protocols; Electroacupuncture; Exercise Therapy; Female; Humans; Middle Aged; Muscle Strength; Pelvic Floor; Prospective Studies; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Incontinence | 2014 |
Comparative effectiveness of combined low- and standard-dose trospium and solifenacin for moderate overactive bladder symptoms in elderly men and women.
Topics: Age Factors; Aged; Benzilates; Drug Therapy, Combination; Female; Humans; Male; Muscarinic Antagonists; Nortropanes; Quinuclidines; Russia; Severity of Illness Index; Sex Factors; Solifenacin Succinate; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics; Urological Agents | 2014 |
Can we decide the optimal initial treatment for male lower urinary tract symptoms patients with overactive bladder by the most bothersome symptom? A randomized, prospective, open-label study.
Topics: Aged; Decision Making; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Prostate; Quality of Life; Quinuclidines; Republic of Korea; Solifenacin Succinate; Sulfonamides; Symptom Assessment; Tamsulosin; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urination | 2014 |
Effect of improvement in lower urinary tract symptoms on sexual function in men: tamsulosin monotherapy vs. combination therapy of tamsulosin and solifenacin.
Topics: Aged; Drug Therapy, Combination; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Quality of Life; Quinuclidines; Rheology; Solifenacin Succinate; Sulfonamides; Surveys and Questionnaires; Tamsulosin; Tetrahydroisoquinolines; Treatment Outcome; Urological Agents | 2014 |
A randomized, double-blind, solifenacin succinate versus placebo control, phase 4, multicenter study evaluating urinary continence after robotic assisted radical prostatectomy.
Topics: Adult; Aged; Double-Blind Method; Humans; Male; Middle Aged; Muscarinic Antagonists; Prostatectomy; Quinuclidines; Robotic Surgical Procedures; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Incontinence | 2015 |
A comparative study on the efficacy of solifenacin succinate in patients with urinary frequency with or without urgency.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2014 |
Decrease of risk of developing symptoms of OAB in elderly men and women treated with loop diuretic for hypertensive disease using solifenacin.
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Female; Furosemide; Humans; Hypertension; Inpatients; Longitudinal Studies; Male; Prospective Studies; Quinuclidines; Risk Factors; Russia; Sodium Potassium Chloride Symporter Inhibitors; Solifenacin Succinate; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics | 2014 |
Validation of the Patient Perception of Intensity of Urgency Scale in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Psychometrics; Quinuclidines; Reproducibility of Results; Severity of Illness Index; Solifenacin Succinate; Sulfonamides; Surveys and Questionnaires; Tamsulosin; Tetrahydroisoquinolines; Urological Agents | 2014 |
The therapeutic effect of solifenacin succinate on the recovery from voiding dysfunction after radical prostatectomy in men with clinically localized prostate cancer: a prospective, randomized, controlled study.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Drug Therapy, Combination; Humans; Male; Midodrine; Muscarinic Antagonists; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Quinuclidines; Recovery of Function; Single-Blind Method; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Incontinence | 2015 |
[Peculiarities of clinical course, diagnostics and treatment of overactive bladder in men older than 60 years].
Topics: Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Prostatitis; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Urological Agents | 2014 |
The effect of solifenacin on postvoid dribbling in women: results of a randomized, double-blind placebo-controlled trial.
Topics: Child; Double-Blind Method; Female; Humans; Muscarinic Antagonists; Quality of Life; Quinuclidines; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Urination | 2018 |
103 other study(ies) available for solifenacin succinate and quinuclidines
| Article | Year |
|---|---|
Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo.
Topics: Animals; Bethanechol; Cholera Toxin; Colonic Diseases, Functional; Defecation; Diarrhea; Dinoprostone; Disease Models, Animal; Intestines; Isoquinolines; Male; Muscarinic Antagonists; Neostigmine; Nicotine; Quinuclidines; Rats; Receptor, Muscarinic M3; Receptors, Muscarinic; Serotonin; Solifenacin Succinate; Stress, Physiological; Tetrahydroisoquinolines | 2001 |
YM905, a novel M3 antagonist, inhibits Ca2+ signaling and c-fos gene expression mediated via muscarinic receptors in human T cells.
Topics: Calcium Signaling; Cells, Cultured; Genes, fos; Humans; Isoquinolines; Muscarinic Antagonists; Oxotremorine; Quinuclidines; Receptor, Muscarinic M3; Receptors, Muscarinic; RNA, Messenger; Solifenacin Succinate; T-Lymphocytes; Tetrahydroisoquinolines | 2000 |
M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.
Topics: Animals; Benzofurans; Bradycardia; Calcium; Carbachol; Cells, Cultured; Cytosol; Dose-Response Relationship, Drug; Female; Guinea Pigs; Humans; In Vitro Techniques; Isoquinolines; Kinetics; Male; Mandelic Acids; Mice; Mice, Inbred BALB C; Muscarinic Antagonists; Muscle Contraction; Muscle, Smooth; Pyrrolidines; Quinuclidines; Rats; Receptor, Muscarinic M3; Receptors, Muscarinic; Salivary Glands; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder | 2002 |
Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells.
Topics: Animals; Benzhydryl Compounds; Benzofurans; Calcium; Calcium Signaling; Carbachol; Cresols; Dose-Response Relationship, Drug; In Vitro Techniques; Inhibitory Concentration 50; Macaca fascicularis; Male; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Submandibular Gland; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder | 2004 |
In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats.
Topics: Animals; Atropine; Benzhydryl Compounds; Benzofurans; Calcium; Cresols; Dose-Response Relationship, Drug; Female; In Vitro Techniques; Mandelic Acids; Muscarinic Antagonists; Myocytes, Smooth Muscle; Organ Specificity; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Rats; Rats, Wistar; Solifenacin Succinate; Submandibular Gland; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder | 2004 |
[In overactive bladder, above all urgency is stressful. The patients know the site of each toilet].
Topics: Cholinergic Antagonists; Humans; Placebos; Quality of Life; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Surveys and Questionnaires; Tetrahydroisoquinolines; Time Factors; Urinary Incontinence; Urination Disorders | 2004 |
[Overactive bladder. New anticholinergic drug controls urinary urge].
Topics: Benzhydryl Compounds; Cresols; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Multicenter Studies as Topic; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Incontinence; Urodynamics | 2004 |
New molecular entity: Vesicare, Yamanouchi/GlaxoSmithKline solifenacin.
Topics: Administration, Oral; Drug Approval; Drug Interactions; Humans; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; United States; United States Food and Drug Administration; Urinary Bladder Diseases | 2005 |
Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice.
Topics: Administration, Oral; Animals; Depression, Chemical; In Vitro Techniques; Male; Mandelic Acids; Mice; Muscarinic Antagonists; Quinuclidines; Radioligand Assay; Receptors, Muscarinic; Salivary Glands; Salivation; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder | 2005 |
Solifenacin and darifenacin for overactive bladder.
Topics: Benzofurans; Drug Interactions; Humans; Intestinal Obstruction; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Incontinence; Xerostomia | 2005 |
Effects of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infarcted rats.
Topics: Animals; Benzhydryl Compounds; Benzilates; Cresols; Infarction, Middle Cerebral Artery; Male; Muscarinic Antagonists; Muscle, Smooth; Phenylpropanolamine; Quinuclidines; Rats; Rats, Sprague-Dawley; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder; Urinary Bladder, Neurogenic | 2005 |
New treatment options for overactive bladder.
Topics: Benzofurans; Clinical Trials as Topic; Humans; Muscarinic Antagonists; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Incontinence | 2005 |
Solifenacin and darifenacin for overactive bladder.
Topics: Benzofurans; Drug Interactions; Humans; Muscarinic Antagonists; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder Diseases; Urinary Incontinence | 2005 |
Synthesis and antimuscarinic properties of quinuclidin-3-yl 1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives as novel muscarinic receptor antagonists.
Topics: Animals; Female; Models, Molecular; Muscarinic Antagonists; Muscle Contraction; Muscle, Smooth; Quinuclidines; Radioligand Assay; Rats; Rats, Wistar; Receptor, Muscarinic M3; Saliva; Solifenacin Succinate; Stereoisomerism; Structure-Activity Relationship; Tetrahydroisoquinolines; Urinary Bladder; Urinary Incontinence | 2005 |
Solifenacin versus tolterodine--a head-to-head study: finally! But not final?
Topics: Benzhydryl Compounds; Cresols; Double-Blind Method; Humans; Muscarinic Antagonists; Phenylpropanolamine; Prospective Studies; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Incontinence | 2005 |
Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study.
Topics: Adult; Area Under Curve; Contraceptives, Oral; Cross-Over Studies; Double-Blind Method; Ethinyl Estradiol; Female; Follicle Stimulating Hormone; Humans; Levonorgestrel; Luteinizing Hormone; Metabolic Clearance Rate; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; White People | 2005 |
Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome
Topics: Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Humans; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Syndrome; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Incontinence | 2006 |
Solifenacin in overactive bladder syndrome: a viewpoint by Scott Serels.
Topics: Humans; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Syndrome; Tetrahydroisoquinolines; Urinary Incontinence | 2005 |
Solifenacin in overactive bladder: a viewpoint by Hashim Hashim.
Topics: Animals; Humans; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Syndrome; Tetrahydroisoquinolines; Urinary Incontinence | 2005 |
New drugs 06, part I.
Topics: Acamprosate; Adenine Nucleotides; Alcohol Deterrents; Amyloid; Analgesics, Non-Narcotic; Anti-HIV Agents; Antifungal Agents; Antineoplastic Agents; Aptamers, Nucleotide; Arabinonucleosides; Azabicyclo Compounds; Benzofurans; Clofarabine; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Echinocandins; Exenatide; Fibroblast Growth Factor 7; Guanine; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Lipopeptides; Lipoproteins; Macular Degeneration; Micafungin; omega-Conotoxins; Patient Education as Topic; Peptides; Peptides, Cyclic; Piperazines; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Stomatitis; Taurine; Tetrahydroisoquinolines; Urinary Incontinence; Venoms | 2006 |
[Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
Topics: Analysis of Variance; Benzhydryl Compounds; Controlled Clinical Trials as Topic; Cresols; Double-Blind Method; Drug Tolerance; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prospective Studies; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2006 |
Comparative evaluation of exocrine muscarinic receptor binding characteristics and inhibition of salivation of solifenacin in mice.
Topics: Administration, Oral; Animals; Kinetics; Male; Mandelic Acids; Mice; Mice, Inbred Strains; Parasympatholytics; Quinuclidines; Receptors, Muscarinic; Saliva; Salivation; Solifenacin Succinate; Tetrahydroisoquinolines | 2006 |
Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis.
Topics: Aged; Gastroesophageal Reflux; Humans; Meta-Analysis as Topic; Muscarinic Antagonists; Quinuclidines; Respiratory Aspiration; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2006 |
Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
Topics: Animals; Atropine; Benzhydryl Compounds; Benzilates; Benzofurans; Binding, Competitive; Carbachol; CHO Cells; Cholinergic Agonists; Cresols; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; In Vitro Techniques; Male; Mandelic Acids; Muscarinic Antagonists; Muscle Contraction; Muscle, Smooth; N-Methylscopolamine; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Muscarinic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Transfection; Urinary Bladder; Urinary Bladder, Overactive; Urination | 2007 |
Pharmacokinetics, safety, and tolerability of solifenacin in patients with renal insufficiency.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Female; Humans; Linear Models; Male; Middle Aged; Muscarinic Antagonists; Orosomucoid; Protein Binding; Quinuclidines; Renal Insufficiency; Solifenacin Succinate; Tetrahydroisoquinolines | 2007 |
Solifenacin succinate (VESIcare): overactive bladder therapy.
Topics: Contraindications; Humans; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2006 |
An unusual cause of postoperative detrusor overactivity.
Topics: Adult; Fallopian Tube Diseases; Female; Humans; Hysterectomy; Muscarinic Antagonists; Prolapse; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urodynamics | 2007 |
[Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
Topics: Analysis of Variance; Benzhydryl Compounds; Cresols; Double-Blind Method; Drug Tolerance; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Prospective Studies; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2007 |
Comparative in vivo uroselectivity profiles of anticholinergics, tested in a novel anesthetized rabbit model.
Topics: Anesthesia; Animals; Benzhydryl Compounds; Benzofurans; Carbachol; Cholinergic Antagonists; Cresols; Injections, Intra-Arterial; Male; Mandelic Acids; Phenylpropanolamine; Pressure; Pyrrolidines; Quinuclidines; Rabbits; Salivary Glands; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder | 2007 |
Determination of solifenacin succinate, a novel muscarinic receptor antagonist, and its major metabolite in rat plasma by semi-micro high performance liquid chromatography.
Topics: Animals; Chromatography, High Pressure Liquid; Drug Stability; Male; Microchemistry; Quinuclidines; Rats; Rats, Inbred F344; Sensitivity and Specificity; Solifenacin Succinate; Tetrahydroisoquinolines | 2007 |
Effects of intravenously and orally administered solifenacin succinate (YM905) on carbachol-induced intravesical pressure elevation and salivary secretion in mice.
Topics: Administration, Oral; Anesthesia; Animals; Blood Pressure; Carbachol; Injections, Intravenous; Mice; Muscarinic Agonists; Muscarinic Antagonists; Quinuclidines; Salivation; Solifenacin Succinate; Tetrahydroisoquinolines | 2007 |
Photodistributed lichenoid drug eruption secondary to solifenacin.
Topics: Anti-Ulcer Agents; Anticholesteremic Agents; Drug Eruptions; Drug Interactions; Humans; Lichenoid Eruptions; Male; Middle Aged; Muscarinic Antagonists; Myocardial Ischemia; Quinine; Quinuclidines; Solifenacin Succinate; Sunscreening Agents; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2008 |
Pharmacological effects of solifenacin on human isolated urinary bladder.
Topics: Aged; Calcium Chloride; Carbachol; Dose-Response Relationship, Drug; Electric Stimulation; Female; Humans; In Vitro Techniques; Male; Microdialysis; Muscarinic Antagonists; Muscle Contraction; Muscle, Smooth; Potassium Chloride; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder | 2008 |
Solifenacin-induced small bowel pseudo-obstruction.
Topics: Aged, 80 and over; Female; Humans; Intestinal Pseudo-Obstruction; Intestine, Small; Muscarinic Antagonists; Positron-Emission Tomography; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tomography, X-Ray; Urinary Bladder, Overactive | 2008 |
Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study.
Topics: Aged; Aged, 80 and over; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Female; Germany; Heart Rate; Humans; Male; Middle Aged; Muscarinic Antagonists; Product Surveillance, Postmarketing; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines | 2008 |
[Overactive bladder. When it's pressing, immediate help is indicated].
Topics: Clinical Trials as Topic; Female; Humans; Male; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urodynamics | 2008 |
The cost utility of solifenacin in the treatment of overactive bladder.
Topics: Adult; Cost-Benefit Analysis; Diapers, Adult; Drug Costs; Female; Humans; Male; Markov Chains; Muscarinic Antagonists; Patient Compliance; Quality-Adjusted Life Years; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2009 |
QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman.
Topics: Aged, 80 and over; Electrocardiography; Female; Humans; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Syncope; Tetrahydroisoquinolines; Torsades de Pointes; Treatment Outcome; Urinary Bladder, Overactive | 2008 |
[Urinary urgency].
Topics: Aged; Clinical Trials as Topic; Female; Humans; Male; Muscarinic Antagonists; Nocturia; Quinuclidines; Sleep Deprivation; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urinary Incontinence, Urge | 2008 |
Highly sensitive and rapid LC-ESI-MS/MS method for the simultaneous quantification of uroselective alpha1-blocker, alfuzosin and an antimuscarinic agent, solifenacin in human plasma.
Topics: Adrenergic alpha-Antagonists; Chromatography, Liquid; Drug Stability; Humans; Male; Methyl Ethers; Muscarinic Antagonists; Propranolol; Quinazolines; Quinuclidines; Reference Standards; Sensitivity and Specificity; Solifenacin Succinate; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tetrahydroisoquinolines | 2008 |
Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa.
Topics: Aged; Benzhydryl Compounds; Benzofurans; Cresols; Cystectomy; Female; Humans; Male; Middle Aged; Mucous Membrane; Muscarinic Antagonists; Phenylpropanolamine; Prostatectomy; Pyrrolidines; Quinuclidines; Quinuclidinyl Benzilate; Radioligand Assay; Receptors, Muscarinic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder; Urinary Bladder, Overactive | 2009 |
Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Humans; Muscarinic Antagonists; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Terminology as Topic; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2009 |
In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder.
Topics: Animals; Atrial Function; Benzhydryl Compounds; Benzofurans; Carbamates; Cresols; Guinea Pigs; In Vitro Techniques; Male; Mice; Muscle Contraction; Muscle, Smooth; Myocardial Contraction; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Receptor, Muscarinic M3; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder | 2009 |
Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Cresols; Decision Support Techniques; Female; Finland; Humans; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Randomized Controlled Trials as Topic; Scandinavian and Nordic Countries; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2009 |
Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin.
Topics: Aged; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2009 |
Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice.
Topics: Administration, Oral; Animals; Dose-Response Relationship, Drug; Male; Mandelic Acids; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Knockout; Muscarinic Antagonists; Protein Binding; Quinuclidines; Radioligand Assay; Receptor, Muscarinic M2; Receptor, Muscarinic M3; Solifenacin Succinate; Submandibular Gland; Tetrahydroisoquinolines; Urinary Bladder | 2009 |
Solifenacin in the treatment of overactive bladder syndrome in Italian patients: pharmacoeconomic evaluation.
Topics: Benzhydryl Compounds; Computer Simulation; Cost-Benefit Analysis; Cresols; Humans; Italy; Markov Chains; Muscarinic Antagonists; Pharmacogenetics; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Incontinence | 2009 |
Anticholinergic drug use for overactive bladder in Sweden: a nationwide pharmacoepidemiological study.
Topics: Benzhydryl Compounds; Benzofurans; Cholinergic Antagonists; Cresols; Female; Health Care Costs; Humans; Muscarinic Antagonists; Pharmacoepidemiology; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Registries; Retrospective Studies; Solifenacin Succinate; Sweden; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2009 |
Solifenacin for therapy resistant overactive bladder.
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Male; Muscarinic Antagonists; Quinuclidines; Retrospective Studies; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2009 |
Response to "Suspected differential interactions of digoxin with imidafenacin and propantheline; some thoughts for introspection".
Topics: Biological Availability; Cholinergic Antagonists; Digoxin; Drug Interactions; Humans; Imidazoles; Propantheline; Quinuclidines; Receptors, Muscarinic; Solifenacin Succinate; Tetrahydroisoquinolines | 2009 |
Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: an exploratory subgroup analysis.
Topics: Aged; Efficiency; Female; Health Resources; Humans; Male; Middle Aged; Prospective Studies; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2009 |
The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Topics: Benzhydryl Compounds; Benzilates; Cost-Benefit Analysis; Cresols; Decision Trees; Delayed-Action Preparations; Humans; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2010 |
Pediatrics: combining antimuscarinics shows promise for overactive bladder.
Topics: Benzhydryl Compounds; Child; Cresols; Drug Therapy, Combination; Humans; Mandelic Acids; Muscarinic Antagonists; Pediatrics; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2010 |
Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urodynamics | 2010 |
Loss of muscarinic and purinergic receptors in urinary bladder of rats with hydrochloric acid-induced cystitis.
Topics: Adenosine Triphosphate; Animals; Benzhydryl Compounds; Benzofurans; Cresols; Cystitis; Disease Models, Animal; Down-Regulation; Female; Hydrochloric Acid; Mandelic Acids; N-Methylscopolamine; Organophosphonates; Phenols; Phenylpropanolamine; Pirenzepine; Polycyclic Compounds; Pyridoxal Phosphate; Pyrrolidines; Quinuclidines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; Receptors, Purinergic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder; Urination; Urodynamics | 2010 |
[Solifenacin in treatment of the overactive bladder syndrome--diagnosis, clinical management and results].
Topics: Aged; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urinary Incontinence | 2010 |
Overactive bladder syndrome: what is the role of evidence of detrusor overactivity in the cystometric study?
Topics: Adult; Aged; Aged, 80 and over; Cystostomy; Female; Humans; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quinuclidines; Solifenacin Succinate; Syndrome; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Stress; Urodynamics | 2010 |
A validated rapid stability-indicating method for the determination of related substances in solifenacin succinate by ultra-fast liquid chromatography.
Topics: Chromatography, Liquid; Drug Contamination; Drug Stability; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines | 2010 |
Determination of solifenacin in human plasma by liquid chromatography-tandem mass spectrometry.
Topics: Adult; Chromatography, High Pressure Liquid; Drug Stability; Humans; Linear Models; Male; Middle Aged; Quinuclidines; Reproducibility of Results; Sensitivity and Specificity; Solifenacin Succinate; Tandem Mass Spectrometry; Tetrahydroisoquinolines | 2010 |
Efficacy and tolerability of solifenacin in patients aged ≥ 65 years with overactive bladder: post-hoc analysis of 2 open-label studies.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Clinical Trials as Topic; Cresols; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2011 |
Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a high-throughput radio receptor bioassay.
Topics: Benzhydryl Compounds; Benzofurans; Biological Assay; Brain; Cognition Disorders; Cresols; Humans; In Vitro Techniques; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate | 2011 |
A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Benzhydryl Compounds; Benzofurans; Blood-Brain Barrier; Brain; Cell Line; Chromatography, High Pressure Liquid; Cresols; Humans; Male; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; Solifenacin Succinate; Tandem Mass Spectrometry; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive | 2011 |
The effect of solifenacin on urethral sphincter morphology.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Imaging, Three-Dimensional; Middle Aged; Muscarinic Antagonists; Organ Size; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Ultrasonography; Urethra; Urinary Incontinence, Stress; Urinary Incontinence, Urge | 2011 |
Solifenacin may improve sleep quality in patients with overactive bladder and sleep disturbance.
Topics: Aged; Humans; Male; Middle Aged; Muscarinic Antagonists; Nocturia; Quinuclidines; Sleep Wake Disorders; Solifenacin Succinate; Surveys and Questionnaires; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urinary Incontinence, Urge | 2011 |
[Treatment for overactive bladder].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Cooperative Behavior; Cross-Sectional Studies; General Practice; Humans; Interdisciplinary Communication; Male; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Quinuclidines; Sex Factors; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urodynamics; Young Adult | 2011 |
Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; Creatinine; Drug Resistance; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Nerve Growth Factor; Quinuclidines; Solifenacin Succinate; Syndrome; Taiwan; Tetrahydroisoquinolines; Time Factors; Treatment Failure; Up-Regulation; Urinary Bladder; Urinary Bladder, Overactive; Young Adult | 2011 |
Solifenacin objectively decreases urinary sensation in women with overactive bladder syndrome.
Topics: Aged; Diagnostic Techniques, Urological; Equipment Design; Female; Follow-Up Studies; Humans; Middle Aged; Muscarinic Antagonists; Predictive Value of Tests; Quinuclidines; Reproducibility of Results; Sensation; Solifenacin Succinate; Syndrome; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics | 2012 |
Co-administration of an α(1) -blocker improves the efficacy and safety of antimuscarinic agents in rats with detrusor overactivity.
Topics: Adrenergic alpha-1 Receptor Antagonists; Analysis of Variance; Animals; Disease Models, Animal; Diterpenes; Drug Therapy, Combination; Female; Infarction, Middle Cerebral Artery; Muscarinic Antagonists; Muscle Contraction; Organ Size; Quinuclidines; Rats; Rats, Sprague-Dawley; Solifenacin Succinate; Statistics, Nonparametric; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder; Urinary Bladder, Overactive | 2011 |
Urothelial/lamina propria spontaneous activity and the role of M3 muscarinic receptors in mediating rate responses to stretch and carbachol.
Topics: Animals; Atropine; Benzhydryl Compounds; Benzofurans; Carbachol; Cresols; Diamines; Mandelic Acids; Mucous Membrane; Muscarinic Antagonists; Muscle Contraction; Phenylpropanolamine; Piperidines; Pirenzepine; Pyrrolidines; Quinuclidines; Receptor, Muscarinic M3; Solifenacin Succinate; Stress, Mechanical; Swine; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder; Urothelium | 2011 |
α-Blockers and antimuscarinics for male lower urinary tract symptoms: the search goes on.
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Lower Urinary Tract Symptoms; Male; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder; Urinary Bladder Neck Obstruction | 2013 |
Finding unrecognized information in overactive bladder clinical trial data: a new approach to understanding placebo and treatment effects.
Topics: Clinical Trials as Topic; Forecasting; Humans; Logistic Models; Models, Biological; Muscarinic Antagonists; Placebo Effect; Placebos; Quinuclidines; Randomized Controlled Trials as Topic; Retrospective Studies; Sample Size; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2013 |
Anticholinergic drugs or botulinum toxin for urge incontinence?
Topics: Botulinum Toxins; Botulinum Toxins, Type A; Cholinergic Antagonists; Female; Humans; Quinuclidines; Randomized Controlled Trials as Topic; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Incontinence, Urge | 2012 |
Effects of solifenacin in patients with neurogenic detrusor overactivity as a result of spinal cord lesion.
Topics: Chi-Square Distribution; Compliance; Female; Humans; Longitudinal Studies; Male; Muscarinic Antagonists; Quinuclidines; Retrospective Studies; Solifenacin Succinate; Spinal Cord Injuries; Switzerland; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics | 2013 |
Overactive bladder medical management in the elderly: it is time to go beyond the tip of the iceberg.
Topics: Aging; Cognition; Cognitive Dysfunction; Female; Humans; Male; Mandelic Acids; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urological Agents | 2013 |
Reply from authors re: Jean-Nicolas Cornu. Overactive bladder medical management in the elderly: it is time to go beyond the tip of the iceberg. Eur Urol 2013;64:82-3.
Topics: Aging; Cognition; Cognitive Dysfunction; Female; Humans; Male; Mandelic Acids; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive; Urological Agents | 2013 |
Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome.
Topics: Aged; Area Under Curve; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Muscarinic Antagonists; Product Surveillance, Postmarketing; Prospective Studies; Quinuclidines; ROC Curve; Sex Factors; Solifenacin Succinate; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Urodynamics; Urological Agents | 2014 |
Male lower urinary tract symptoms: a riddle waiting to be solved.
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Lower Urinary Tract Symptoms; Male; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder; Urination Disorders; Urological Agents | 2013 |
Bitterness evaluation of intact and crushed Vesicare orally disintegrating tablets using taste sensors.
Topics: Administration, Oral; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Particle Size; Quinuclidines; Solifenacin Succinate; Tablets; Taste; Tetrahydroisoquinolines; Time Factors; Urological Agents | 2013 |
Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Benzofurans; Cholinergic Antagonists; Cresols; Databases, Pharmaceutical; Drug Substitution; Female; Follow-Up Studies; Humans; Medication Adherence; Middle Aged; Norway; Phenylpropanolamine; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder, Overactive; Young Adult | 2013 |
Reply from authors re: Apostolos Apostolidis. Male lower urinary tract symptoms: a riddle waiting to be solved. Eur Urol 2013;64:408-10: a rationale for combination antimuscarinic-α-blocker therapy for male lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Lower Urinary Tract Symptoms; Male; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder; Urination Disorders; Urological Agents | 2013 |
Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom.
Topics: Benzhydryl Compounds; Cohort Studies; Cost-Benefit Analysis; Cresols; Humans; Incontinence Pads; Mandelic Acids; Markov Chains; Medication Adherence; Models, Economic; Muscarinic Antagonists; Patient Dropouts; Phenylpropanolamine; Quality-Adjusted Life Years; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; United Kingdom; Urinary Bladder, Overactive; Urinary Incontinence | 2013 |
Risk factors for the failure of antimuscarinic treatment with solifenacin in women with overactive bladder.
Topics: Aged; Female; Humans; Middle Aged; Multivariate Analysis; Muscarinic Antagonists; Prospective Studies; Quality of Life; Quinuclidines; Risk Factors; Solifenacin Succinate; Surveys and Questionnaires; Tetrahydroisoquinolines; Time Factors; Treatment Failure; Treatment Outcome; Urinary Bladder, Overactive; Urination | 2013 |
Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Benzilates; Cresols; Cross-Sectional Studies; Female; Humans; Imidazoles; Japan; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Phenylpropanolamine; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive | 2014 |
Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.
Topics: Activities of Daily Living; Adult; Aged; Benzhydryl Compounds; Comorbidity; Cresols; Cross-Sectional Studies; Drug Substitution; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Muscarinic Antagonists; Observational Studies as Topic; Patient Preference; Patient Satisfaction; Personal Satisfaction; Phenylpropanolamine; Physicians; Propensity Score; Quinuclidines; Retrospective Studies; Sample Size; Solifenacin Succinate; Tetrahydroisoquinolines; Therapeutic Equivalency; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents; Young Adult | 2014 |
Patient-reported outcome of solifenacin treatment among women experiencing urinary urgency and urgency incontinence.
Topics: Adult; Aged; Female; Humans; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Pilot Projects; Prospective Studies; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Incontinence, Urge | 2014 |
Efficacy and tolerability of solifenacin in men with overactive bladder: results of an observational study.
Topics: Adult; Aged; Aged, 80 and over; Cognition; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Prospective Studies; Quality of Life; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2014 |
Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain.
Topics: Aged; Benzhydryl Compounds; Cholinergic Agents; Cost-Benefit Analysis; Cresols; Female; Health Care Costs; Humans; Male; Phenylpropanolamine; Prevalence; Primary Health Care; Quinuclidines; Retrospective Studies; Solifenacin Succinate; Spain; Syndrome; Tetrahydroisoquinolines; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2013 |
Solifenacin in women with de novo overactive bladder after tension-free obturator vaginal tape--is it effective?
Topics: Aged; Aged, 80 and over; Female; Humans; Middle Aged; Muscarinic Antagonists; Postoperative Complications; Prospective Studies; Quinuclidines; Solifenacin Succinate; Suburethral Slings; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2014 |
Impact of symptom improvement on patients' bother and quality of life in female patients with overactive bladder treated by solifenacin (SET-Q).
Topics: Aged; Aged, 80 and over; Female; Humans; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quality of Life; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Surveys and Questionnaires; Symptom Assessment; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2014 |
Bladder and erectile dysfunctions in the Type 2 diabetic Goto-Kakizaki rat.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Type 2; Erectile Dysfunction; Male; Penile Erection; Piperazines; Purines; Quinuclidines; Rats; Rats, Wistar; Sildenafil Citrate; Solifenacin Succinate; Sulfones; Tetrahydroisoquinolines; Urinary Bladder; Urinary Bladder Diseases; Urination; Urological Agents; Vasodilator Agents | 2014 |
Managing overactive bladder symptoms in a palliative care setting.
Topics: Aged, 80 and over; Butylscopolammonium Bromide; Cholinergic Antagonists; Humans; Incontinence Pads; Male; Muscarinic Antagonists; Palliative Care; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder Neoplasms; Urinary Bladder, Overactive; Urinary Tract Infections | 2014 |
Overactive bladder symptom score to evaluate efficacy of solifenacin for the treatment of overactive bladder symptoms.
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2014 |
The cost-effectiveness of solifenacin vs. trospium in the treatment of patients with overactive bladder in the German National Health Service.
Topics: Benzilates; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Germany; Health Services; Humans; Medication Adherence; Models, Economic; National Health Programs; Nortropanes; Quality-Adjusted Life Years; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; United Kingdom; Urinary Bladder, Overactive; Urological Agents | 2014 |
The effect of oral solifenacin succinate treatment on intraocular pressure: glaucoma paradox during overactive bladder treatment.
Topics: Adult; Aged; Aged, 80 and over; Female; Glaucoma; Humans; Intraocular Pressure; Middle Aged; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2014 |
Persistence with solifenacin add-on therapy in men with benign prostate obstruction and residual symptoms of overactive bladder after tamsulosin monotherapy.
Topics: Drug Therapy, Combination; Humans; Male; Muscarinic Antagonists; Prostatic Hyperplasia; Quinuclidines; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2014 |
Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Benzhydryl Compounds; Cresols; Family Practice; Humans; Lower Urinary Tract Symptoms; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Phenylpropanolamine; Primary Health Care; Prostatic Hyperplasia; Quinuclidines; Retrospective Studies; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Tolterodine Tartrate; United Kingdom | 2015 |
A prospective, observational study to assess the association between dry mouth and solifenacin treatment in patients with overactive bladder syndrome.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Prospective Studies; Quinuclidines; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Xerostomia; Young Adult | 2015 |
Anti-muscarinic adjunct therapy accelerates functional human oligodendrocyte repair.
Topics: Animals; Brain Stem; Cells, Cultured; DNA-Binding Proteins; Evoked Potentials, Auditory, Brain Stem; Female; Fetal Stem Cells; Humans; Male; Mice; Muscarinic Agonists; Muscarinic Antagonists; Myelin Sheath; Neurogenesis; O Antigens; Oligodendroglia; Prosencephalon; Quinuclidines; Receptor, Muscarinic M3; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Muscarinic; Regeneration; Solifenacin Succinate; Tetrahydroisoquinolines | 2015 |
Solifenacin or mirabegron could improve persistent overactive bladder symptoms after dutasteride treatment in patients with benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Aged, 80 and over; Azasteroids; Dutasteride; Humans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Prostatic Hyperplasia; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Thiazoles; Urinary Bladder, Overactive | 2015 |
[ASSESSMENT OF EFFICIENCY OF TREATMENT OF OVERACTIVE BLADDER IN ELDERLY PATIENTS].
Topics: Adrenergic alpha-1 Receptor Antagonists; Age Factors; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Muscarinic Antagonists; Prazosin; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive; Urination | 2015 |
Long-term prospective study of the persistence of solifenacin succinate in previously untreated Japanese female patients with overactive bladder.
Topics: Female; Humans; Medication Adherence; Muscarinic Antagonists; Prospective Studies; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Treatment Outcome; Urinary Bladder, Overactive | 2016 |
Re: Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
Topics: Acetanilides; Double-Blind Method; Humans; Muscarinic Antagonists; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive | 2016 |
Re: Effectiveness of Solifenacin and Trospium for Managing of Severe Symptoms of Overactive Bladder in Patients with Benign Prostatic Hyperplasia.
Topics: Humans; Male; Muscarinic Antagonists; Prostatic Hyperplasia; Quinuclidines; Solifenacin Succinate; Urinary Bladder, Overactive | 2017 |